CatalystAlertBeta

Briefing Calendar News IPOs Opportunities Companies Compare Analytics Watchlist Learn

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar with AI-powered predictions. Track FDA decisions, PDUFA dates, clinical trial results, and Phase 3 readouts. Real-time alerts for biotech investors.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Short Interest
Smart Money
Biotech Glossary

Legal

About
ML Track Record
Privacy
Terms
Cookies

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

Follow Us

⚠️ Important Legal Disclaimer

Not Financial Advice: CatalystAlert is an informational platform only. We are NOT a registered investment advisor, broker, or dealer. The information provided on this website does not constitute investment advice, financial advice, trading advice, or any other sort of advice, and you should not treat any of the website's content as such.

No Guarantees: All predictions, probability scores, and analyses are based on historical data and machine learning models. Past performance does NOT guarantee future results. Biotech investing is extremely high-risk and you may lose your entire investment.

Data Accuracy: While we strive for accuracy, data may be incomplete, delayed, or contain errors. We aggregate data from third-party sources (FDA, SEC, ClinicalTrials.gov) and are not responsible for their accuracy. Always verify information with official sources before making any decisions.

Your Responsibility: You are solely responsible for your investment decisions. Consult a qualified financial advisor before investing. CatalystAlert and its operators accept no liability for any losses incurred from using this platform.

© 2026 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.

Home Calendar News Learn Account

OTX-TKI (axitinib implant) - Phase 3 | OCUL Pipeline | CatalystAlert

OTX-TKI (axitinib implant)

Phase 3

Ocular Therapeutix, Inc. (OCUL)

00%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

2

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

2mo

OCULPhase 3$1.1B

✓Positive

OTX-TKI (axitinib implant) Phase 3 Results Expected

OTX-TKI (axitinib implant)• Neovascular Age-Related Macular Degeneration344

Apr 29Estimated

Competitive Landscape

3 competitors in Neovascular Age-Related Macular Degeneration

NVSAflibercept 2 mg

CLSDAflibercept

View Full Landscape

Drug Information

Target Indication

Neovascular Age-Related Macular Degeneration

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA9/19/2024

Axitinib Accord

Axitinib Accord is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.

EMA9/3/2012

Inlyta

Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.

Drug Science

Mechanism of action & safety profile

Developer

OCUL

Ocular Therapeutix, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Ophthalmic InsertPhase 3

Open Angle Glaucoma and Ocular Hypertension

Punctum PlugPhase 3

Post Ocular Surgical Inflammation and Pain

DexamethasonePhase 3

Post-Surgical Ocular Pain

Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24Phase 3

Non-Proliferative Diabetic Retinopathy

Dextenza Ophthalmic InsertPhase 3

Cataract

View full pipeline